The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites

Biomedicine and Pharmacotherapy

Volumn 47, Issue 8, 1993, Pages 345-352

  Toschi, V ^a   Rocchini, G M ^a   Motta, A ^a   Fiorini, G F ^c   Cimminiello, C ^b   Violi, F ^d   Castelli, C ^a   Sironi, D ^c   Gibelli, A ^a  

^a Department of Haematology and Blood Transfusion ^*  (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c Division of Internal Medicine Ospedale F Villa ^*  (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

hyperfibrinolysis; liver cirrhosis; PAI 1

Indexed keywords

FIBRINOGEN; FIBRINOPEPTIDE A; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; ASCITES; BLOOD CLOTTING; CLINICAL ARTICLE; FEMALE; FIBRINOLYSIS; HUMAN; LIVER CIRRHOSIS; MALE; PATHOGENESIS; PERITONEAL FLUID; PLASMA; PRIORITY JOURNAL;

ADULT; AGED; ASCITES; ASCITIC FLUID; BLOOD COAGULATION FACTORS; FEMALE; FIBRINOLYSIS; HUMAN; LIVER CIRRHOSIS; MALE; MIDDLE AGE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 0027146561     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/0753-3322(93)90084-X     Document Type: Article

References (35)

1. The fibrin plate method for estimating fibrinolytic activity
2. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage
3. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator
4. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man
5. Antithrombin III infusion in patients undergoing peritoneovenous shunt operation: failure in the prevention of disseminated intravascular coagulation
6. Gerinnungsphysiologische schnelImethode zur Bestimmung des Fibrinogens
7. Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients
8. Prekallikrein and factor VII as prognostic indexes of liver failure
9. Determinants of clearance of tissue-type plasminogen activator (t-PA) from the circulation
10. Exchange of macromolecules between peritoneal cavity and plasma
11. Clinical significance of accelerated fibrinolysis in liver disease
12. Relation of intraperitoneal and intravascular coagulation and fibrinolysis related antigens in peritoneal dialysis
13. Analysis of twenty-three plasma proteins in ascites. The depletion of fibrinogen and plasminogen
14. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor
15. Haemostatic problems in liver disease
16. Alpha 2-plasmin inhibitor metabolism in patients with liver cirrhosis
17. Identification des produits de dégradation du fibrinogène ou de la fibrine dans le liquide d'ascite
18. Different molecular weight forms of tissue-type plasminogen activator in ascitic fluid from patients with liver cirrhosis
19. Plasminogen activator inhibitor-1 messenger RNA expression is induced in rat hepatocytes in vivo by dexamethasone
20. Tissue plasminogen activator and plasminogen activator inhibitor in patients with liver cirrhosis
21. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis
22. Low grade DIC in liver cirrhosis: fact or fiction?
23. In vivo metabolism of human tissue-type plasminogen activator
24. Intravascular coagulation in autopsy cases with liver diseases
25. Fibrinolytic study in plasma and ascitic fluid in cirrhotic patients before and after ascites concentration; reinfusion technique
26. Transection of the oesophagus for bleeding cesophageal varices
27. Antithrombin III transfusion in patients with hepatic cirrhosis
28. Proteases and antiproteases related to the coagulation system in plasma and ascites
29. Plasminogen activator inhibitors
30. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis
31. Reduced human peritoneal plasminogen activating activity: possible mechanism of adhesion formation
32. Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells
33. The extent of diffuse intravascular coagulation and fibrinolysis in patients with liver cirrhosis
34. Evaluation of D-Dimer in patients with liver cirrhosis
35. Peritoneal fibrinolytic activity and intra-abdominal adhesion